Image 165

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Applicant:

Andrew P. LE'

Serial No.:

09/903,463

Filed:

July 11, 2001

For:

Novel Antioxidant, Nucleic Acid Constructs

Encoding Same, Pharmaceutical Compositions Containing Same and Use of Same for

Reducing Oxidative-Stress

Examiner:

Sheridan Snedden

Group Art Unit: 1653

Attorney

Docket: 01/22194

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Enclosed is a PTO Form 1449 which lists citations which may be material to the patentability and examination of the above identified application. Also enclosed are copies of the references cited. These are submitted in compliance with the duty of disclosure defined in 37 CFR 1.56. The Examiner is requested to make these citations of official record in this application.

Each item contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three (3) months prior to the filing of this Information Disclosure Statement.

This Information Disclosure Statement under 37 CFR 1.56 is not to be construed as a representation that a search has been made, that additional matter which is material to the examination of this application does not exist, or that any or more of these citations constitutes prior art.

Respectfully submitted,

Sol Sheinbein

Registration No. 25,457

Date: November 30, 2003

PTO/SB/08A (10-96)

Approved for use through 10/31/99 OMB 0651-0031 Vatent and Trademark Office: U.S. DEPARTMENT Of COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to re formation unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

SUPPLEMENTAL INFORMATION DISCLOSURE

STATEMENT BY APPLICANT

Complete if Known Application Number 09/903,463 Filing Date 07/1/2001 First Named Inventor **LEVY** Group Art Unit 1653

				Group Art Unit	1653
(use as many sheets as necessary)				Examiner Name	Sheridan Snedden
Sheet	1	Of	1	Attorney Docket Number	01/2194
<u> </u>		OTHER PRIOR ART – NON	PATENT LITER	ATURE DOCUMENTS	
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			T^2
		Melamed-Frank et al, "Structure-Function Analysis of the Antioxidant Properties of Haptoglobin", <i>Blood</i> , 98(13):3693-3698, 2001			
		Langlois et al, "Biological and Clinical Significance of Haptoglobin Polymorphism in Humans", Clinical Chemistry, 42(10):1589-1600, 1996			
	1				
T					
Examiner Signature				Date Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{1.} Unique citation designation number. 2. Applicant is to place a check mark here if English language Translation is attached.